Biofrontera Inc. Common Stock (BFRI) is a publicly traded Healthcare sector company. As of May 21, 2026, BFRI trades at $0.81 with a market cap of $9.54M and a P/E ratio of -0.77. BFRI moved +0.51% today. Year to date, BFRI is +1.23%; over the trailing twelve months it is +22.43%. Its 52-week range spans $0.54 to $2.22. Analyst consensus is buy with an average price target of $9.00. Rallies surfaces BFRI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biofrontera Q1 Revenues Up 17% to $10.1M, Gross Margin at 80%: Biofrontera reported Q1 product revenues of $10.1 million, up 17% year-over-year, with gross margin expanding to about 80% versus 62%. The company achieved near-zero operating cash burn, but recorded a $4.8 million net loss, noted a going concern risk and faces patent litigation expenses.
| Metric | Value |
|---|---|
| Price | $0.81 |
| Market Cap | $9.54M |
| P/E Ratio | -0.77 |
| EPS | $-1.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.22 |
| 52-Week Low | $0.54 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $41.70M |
| Net Income | $-10.54M |
| Gross Margin | 0.00% |
1 analysts cover BFRI: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.00.